Get the Stockscreener App
11.48
16.27%
-2.23
After Hours:
11.50
0.02
+0.17%
Bioventus Inc stock is traded at $11.48, with a volume of 2.18M.
It is down -16.27% in the last 24 hours and down -2.30% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$13.71
Open:
$9.48
24h Volume:
2.18M
Relative Volume:
3.70
Market Cap:
$723.71M
Revenue:
$512.35M
Net Income/Loss:
$-156.23M
P/E Ratio:
-2.5066
EPS:
-4.58
Net Cash Flow:
$7.98M
1W Performance:
-13.75%
1M Performance:
-2.30%
6M Performance:
+189.17%
1Y Performance:
+198.96%
1-Day Range:
$7.30
$11.80
1-Week Range:
$7.30
$14.38
52-Week Range:
$3.36
$14.38
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Bioventus (NYSE:BVS) Shares Gap DownHere's What Happened - MarketBeat
How Are Things Looking For Bioventus Inc (NASDAQ: BVS) For The Short Term? - Stocks Register
BVSBioventus Inc. Latest Stock News & Market Updates - StockTitan
Bioventus: Q3 Earnings Snapshot - San Francisco Chronicle
Bioventus Inc Reports Q3 2024 Earnings: Revenue Hits $139 Millio - GuruFocus.com
Bioventus (NYSE:BVS) Updates FY 2024 Earnings Guidance - MarketBeat
Bioventus Reports Third Quarter Financial Results - The Manila Times
Bioventus reports Q3 adjusted EPS 6c, consensus 3c - TipRanks
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Bioventus Inc (BVS) Q3 2024 Earnings Report Preview: What To Loo - GuruFocus.com
Bioventus Inc (BVS) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Bioventus stock soars to 52-week high, hits $13.65 - Investing.com India
Bioventus stock soars to 52-week high, hits $13.65 By Investing.com - Investing.com South Africa
Bioventus (BVS) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings? - MSN
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 - The Manila Times
Long Term Trading Analysis for (BVS) - Stock Traders Daily
Bioventus (NYSE:BVS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Bioventus stock soars to 52-week high, hits $13.14 - Investing.com India
SG Americas Securities LLC Lowers Stock Position in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus Surges 73% in Three Months: Time to Buy the Stock? - Yahoo Finance
Are Medical Stocks Lagging ChromaDex (CDXC) This Year? - Yahoo Finance
Bioventus stock soars to 52-week high of $12.43 amid growth By Investing.com - Investing.com South Africa
Bioventus (NYSE:BVS) Reaches New 52-Week HighStill a Buy? - MarketBeat
Bioventus stock soars to 52-week high of $12.43 amid growth - Investing.com Australia
Dimensional Fund Advisors LP Buys 58,954 Shares of Bioventus Inc. (NYSE:BVS) - MarketBeat
Bone Growth Products Global Market Report |Bioventus, Djo, Johnson & Johnson, Medtronic, Orthofix, Stryker, Zimmer Biome – IndiaPolitics.com - IndiaPolitics.com
Bioventus (NYSE:BVS) Trading Up 7.5%Here's What Happened - MarketBeat
Bioventus (NYSE:BVS) Shares Up 7.5%What's Next? - MarketBeat
Buying Buzz: Bioventus Inc [BVS] Director Bartholdson John A. acquires 80,000 shares of the company - Knox Daily
Ratio Revelations: Bioventus Inc (BVS)’s Financial Metrics in the Spotlight - The Dwinnex
Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Bank of Montreal Can Invests $774,000 in Bioventus Inc. (NYSE:BVS) - MarketBeat
Marshall Wace LLP Has $1.91 Million Position in Bioventus Inc. (NYSE:BVS) - MarketBeat
U.S. Osteoarthritis Injectables Market Analysis 2024-2030: Rising Prevalence of Osteoarthritis & Increase in R&D Activities for Injectable Drug Developments Spurs Growth - GlobeNewswire Inc.
Bioventus maintains Buy rating by Canaccord Genuity - Investing.com Canada
Bioventus Announces Divestiture Of Its Advanced Rehabilitation Business To Accelmed Partners - citybiz
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - The Manila Times
Bioventus Inc. (NYSE:BVS) Holdings Reduced by Nantahala Capital Management LLC - MarketBeat
Bioventus Inc (BVS) receives a Buy rating from Canaccord Genuity - Knox Daily
Bioventus Inc. (NYSE:BVS) Shares Bought by Rhumbline Advisers - MarketBeat
Bioventus stock soars to 52-week high, hits $12.15 - Investing.com
Bioventus (NYSE:BVS) Hits New 1-Year High After Analyst Upgrade - MarketBeat
Bioventus stock soars to 52-week high, hits $12.15 By Investing.com - Investing.com UK
Bioventus (NYSE:BVS) Price Target Increased to $17.00 by Analysts at Craig Hallum - MarketBeat
(BVS) Technical Data - Stock Traders Daily
Zacks.com featured highlights include Bioventus, Great Lakes Dredge & Dock and AxoGen - Yahoo Finance
Bank of New York Mellon Corp Invests $647,000 in Bioventus Inc. (NYSE:BVS) - MarketBeat
The Attractiveness of Investing In Bioventus Inc (BVS) is Growing - Knox Daily
First September Gains in 5 Years? Buy 3 Breakout Stocks Now - Yahoo Finance
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):